Objective, peer-reviewed reporting on therapeutic peptides, regulatory updates, clinical trial results, and scientific consensus. No hype. No product sales.
Articles tagged weight loss.
Oral GLP-1 pills are trending as elecoglipron trial data raise a serious question: will tablets broaden access to GLP-1 weight-loss and diabetes therapy?
A new ENDO 2026 wearable-data study found GLP-1 users lost weight but moved less. Alex Keane explains why steps, resistance training, and muscle protection now matter.
Oral GLP-1 pill elecoglipron is trending after new Phase 2 data. Here is what it means for peptide science, injections, and metabolic medicine.
The FDA peptide reclassification 2026 is a game-changer. Key peptides are moving from Category 2 to Category 1, signaling a new era for therapeutic access. What does this mean for patients and the future of health science?
No articles match that search.